research A clinical case of familial alopecia areata in combination with immune pathology
Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
Search
for
Sort by
Research
750-780 / 1000+ results research Case report: Novel p.Val306Met missense mutation in TRPV3 in a case of Olmsted syndrome accompanied by squamous cell carcinoma
A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.
research Novel mutation in PTCH1 gene in a patient with basal cell nevus syndrome and uterus bicornis
research When bugs and drugs conspire: driving acneiform skin toxicity
Certain cancer drugs interact with skin bacteria to cause acne-like rashes.
research Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
Baricitinib is the most effective treatment for alopecia areata.
research Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Protein Kinase C Downregulation upon Rapamycin Treatment Attenuates Neuroinflammation and Mitochondrial Disease
Rapamycin treatment helps reduce brain inflammation and symptoms of mitochondrial disease by blocking specific pathways in mice.
research 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
research Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib
Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
research HtrA1L364P leads to cognitive dysfunction and vascular destruction through TGF‐β/Smad signaling pathway in CARASIL model mice
The HtrA1L364P mutation causes brain dysfunction and blood vessel damage.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research Reversible Activation of c-Myc in Skin
Activating c-Myc in skin causes rapid cell growth and changes, but these effects are reversible.
research Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
research Immunohistochemical Analysis of the Mechanistic Target of Rapamycin and Hypoxia Signalling Pathways in Basal Cell Carcinoma and Trichoepithelioma
The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.
research A rare case of multiple keratoacanthomas treated with oral acitretin and intralesional methotrexate
A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
research Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
research Risk of autoimmune diseases in patients with RASopathies: systematic study of humoral and cellular immunity
Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.
research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
research Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
research Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
research Primary TSC2-/meth Cells Induce Follicular Neogenesis in an Innovative TSC Mouse Model
TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
research Recovery of nail dystrophy potential new therapeutic indication of tofacitinib
Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
research Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.